by Pasteur Institute Antibody fragments of EPCT112 bNAb (blue) discovered at the Institut Pasteur by Hugo Mouquet’s team, here forming a complex with the HIV-1 envelope protein (Env) (shown in yellow and orange). Credit: (c) Institut Pasteur / Hugo Mouquet Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to...
(HealthDay)—Amongpatients with multidrug-resistant HIV-1 infection who have limited therapy options, reductions in HIV-1 RNA level were significantly greater in those who received fostemsavir compared with placebo during the first eight days, according to a study published in the March 26 issue of the New England Journal of Medicine. Michael Kozal, M.D., from the Yale University...
